TheraRadar
← Back
Data updated: Jun 12, 2026

TARO PHARM INDS LTD

Generics

TARO PHARM INDS LTD is a generic drug manufacturer focused on Neurology, Cardiovascular, Immunology.

1998
Since
11
Drugs
-
Trials
0
New Drugs (2yr)

TARO PHARM INDS LTD's Key Drugs

TARO PHARM INDS LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

TARO PHARM INDS LTD's Recent FDA Approvals

New NDA/BLA approvals for TARO PHARM INDS LTD over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

TARO PHARM INDS LTD's Therapeutic Areas

TARO PHARM INDS LTD's approved drugs and pipeline span 4 therapeutic areas, led by Neurology and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 40%
2 drugs
Cardiovascular 20%
1 drugs
Immunology 20%
1 drugs
Dermatology 20%
1 drugs

TARO PHARM INDS LTD's Top Competitors

TARO PHARM INDS LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

TARO PHARM INDS LTD Pipeline Snapshot

Active clinical trials for TARO PHARM INDS LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling